



## ONGOING CLINICAL DEVELOPMENTS

Due to the flexibility of its core lentiviral-vector platform, THERAVECTYS has initiated in 2014 an ambitious R&D program to develop a number of therapeutic vaccine candidates against cancers and major global infectious diseases.

INFECTIOUS DISEASES	Pre-clinical	Phase I	Phase II	OTHER IMMUNOTHERAPIES	Pre-clinical	Phase I
Therapeutic anti-HIV			✱	CAR: CLL & ALL (CD19)		✱
Therapeutic MDR Tuberculosis	✱			CAR: AML (CD33-CD123)	✱	
Therapeutic anti-HBV	✱			Anti-checkpoint: PD1, PDL1, CTLA4	✱	

ONCOLOGY	Pre-clinical	Phase I	Tumors	Synergies
HTLV-1 virally-induced Leukemia (ATLL)		✱	liquid	
HPV virally-induced cancer (ENT & cervix)	✱		solid	anti-checkpoint
EBV virally-induced cancer (NPC)	✱		liquid & solid	
Bladder cancer	✱		solid	anti-checkpoint
Renal cell carcinoma (RCC)	✱		solid	anti-checkpoint
Prostate cancer	✱		solid	anti-checkpoint
Melanoma	✱		solid	anti-checkpoint
Ovarian cancer	✱		solid	anti-checkpoint
Breast Cancer	✱		solid	anti-checkpoint
Glioblastoma multiform (GBM)	✱		solid	anti-checkpoint
Mutiple myeloma	✱		liquid	anti-checkpoint
Hepatocellular carcinoma (HCC)	✱		solid	anti-checkpoint
Colorectal cancer	✱		solid	anti-checkpoint

## NEXT STEPS

THERAVECTYS has recently achieved the human proof-of-concept of its lentiviral-vector technology with a recently completed phase I/II study of a therapeutic vaccine against HIV.

The company is now advancing further therapeutic vaccine candidates into the clinics, both in oncology & infection diseases.

THERAVECTYS first oncology clinical trial will target Adult T-cell Leukemia/ Lymphoma virally-induced by HTLV-1 and will enter the clinics in 2015.

This program will be closely followed by a number of therapeutic vaccine candidates in a variety of virally-induced, liquid and solid forms of cancers, including at least one candidate based on the company's proprietary inducible CAR technology.